Cargando…

Response to baricitinib based on prior biologic use in patients with refractory rheumatoid arthritis

OBJECTIVE: RA patients who have failed biologic DMARDs (bDMARDs) represent an unmet medical need. We evaluated the effects of baseline characteristics, including prior bDMARD exposure, on baricitinib efficacy and safety. METHODS: RA-BEACON patients (previously reported) had moderate to severe RA wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Genovese, Mark C, Kremer, Joel M, Kartman, Cynthia E, Schlichting, Douglas E, Xie, Li, Carmack, Tara, Pantojas, Carlos, Sanchez Burson, Juan, Tony, Hans-Peter, Macias, William L, Rooney, Terence P, Smolen, Josef S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Basic and Translational Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5913638/ https://www.ncbi.nlm.nih.gov/pubmed/29415145 http://dx.doi.org/10.1093/rheumatology/kex489

Ejemplares similares

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)
por: Smolen, Josef S, et al.
Publicado: (2017)

Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Correction to: Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2020)

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
por: Schiff, Michael, et al.
Publicado: (2017)

Safety and efficacy of baricitinib in elderly patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2017)

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment
por: Fleischmann, Roy, et al.
Publicado: (2017)

Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
por: Takeuchi, Tsutomu, et al.
Publicado: (2019)

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
por: Keystone, Edward C, et al.
Publicado: (2015)

Characterization and Changes of Lymphocyte Subsets in Baricitinib‐Treated Patients With Rheumatoid Arthritis: An Integrated Analysis
por: Tanaka, Yoshiya, et al.
Publicado: (2018)

Dose/Exposure‐Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis
por: Zhang, Xin, et al.
Publicado: (2017)

Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis
por: Harigai, Masayoshi, et al.
Publicado: (2020)

Evaluation of pneumococcal and tetanus vaccine responses in patients with rheumatoid arthritis receiving baricitinib: results from a long-term extension trial substudy
por: Winthrop, Kevin L., et al.
Publicado: (2019)

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
por: Taylor, Peter C, et al.
Publicado: (2018)

Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis
por: Taylor, Peter C., et al.
Publicado: (2019)

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2017)

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus
por: Alexander, Tobias, et al.
Publicado: (2015)

Use of rituximab, temozolomide, and radiation in recurrent and refractory primary central nervous system lymphoma in the Philippines: a retrospective analysis
por: Batara, Julette Marie F, et al.
Publicado: (2022)

Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics
por: Kremer, Joel M, et al.
Publicado: (2018)

Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis
por: Bell, G M, et al.
Publicado: (2017)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Notch signalling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2
por: Gao, Wei, et al.
Publicado: (2013)

Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis
por: Harry, Rachel A, et al.
Publicado: (2010)

Monocyte migration to the synovium in rheumatoid arthritis patients treated with adalimumab
por: Herenius, M M J, et al.
Publicado: (2011)

Survival rates of children and young adolescents with CNS tumors improved in the Netherlands since 1990: A population-based study
por: Hoogendijk, Raoull, et al.
Publicado: (2021)

Effectiveness of Baricitinib in Refractory Seronegative Rheumatoid Arthritis and Uveitis: A Case Report
por: Kaneko, Yutaka, et al.
Publicado: (2022)

Targeted delivery of cytokine therapy to rheumatoid tissue by a synovial targeting peptide
por: Wythe, Sarah E, et al.
Publicado: (2013)

Non-classical monocytes as mediators of tissue destruction in arthritis
por: Puchner, Antonia, et al.
Publicado: (2018)

Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis
por: Greven, D E A, et al.
Publicado: (2015)

Effects of baricitinib on radiographic progression of structural joint damage at 1 year in patients with rheumatoid arthritis and an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
por: van der Heijde, Desirée, et al.
Publicado: (2018)

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial
por: Michaud, Kaleb, et al.
Publicado: (2019)

MICL controls inflammation in rheumatoid arthritis
por: Redelinghuys, Pierre, et al.
Publicado: (2016)

Baricitinib is potentially effective in the treatment of refractory livedoid vasculopathy
por: Han, Yuyang, et al.
Publicado: (2022)

Efficacy and safety of baricitinib in patients with refractory alopecia areata
por: Wang, Yuqian, et al.
Publicado: (2022)

Single-cell transcriptomic analyses provide insights into the cellular origins and drivers of brain metastasis from lung adenocarcinoma
por: Wang, Zihao, et al.
Publicado: (2023)

GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data
por: Ajaib, Shoaib, et al.
Publicado: (2023)

Novel gene variants associated with cardiovascular disease in systemic lupus erythematosus and rheumatoid arthritis
por: Leonard, Dag, et al.
Publicado: (2018)

Effect of the oral application of a highly selective MMP-13 inhibitor in three different animal models of rheumatoid arthritis
por: Jüngel, Astrid, et al.
Publicado: (2009)

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study
por: Dougados, Maxime, et al.
Publicado: (2017)

Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis
por: Filková, Mária, et al.
Publicado: (2014)

Dominant B cell receptor clones in peripheral blood predict onset of arthritis in individuals at risk for rheumatoid arthritis
por: Tak, Paul P, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_peb71l66mtf0vq9o6j2l1tqqo1